Date: 2014-09-04
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in mAbs
Company: GamaMabs Pharma (France)
Product: 12G4 monoclonal antibody
Action mechanism:
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 4, 2014, GamaMabs Pharma, which holds exclusive rights on 12G4 monoclonal antibodies targeting AMHR2 / MISR2, announced the publication of an article in mAbs (Vol. 6, Issue 5, 2014) by IRCM and ICM teams (France). The article, “The human Müllerian inhibiting substance type 2 receptor as immunotherapy target for Ovarian Cancer: validation using the mAb 12G4”, N Kersual / I Navarro-Teulon, is published in mAbs (Vol. 6, Issue 5, 2014) by IRCM and ICM teams (France) shows that the 12G4 murine antibody targeting AMHR2 increases the survival of mice bearing ovarian tumor and confirms AMHR2 as a promising target for ovarian cancer treatment.
